ProfileGDS4814 / ILMN_2146389
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 12% 3% 8% 15% 22% 29% 17% 17% 43% 16% 8% 15% 24% 6% 19% 22% 5% 8% 2% 21% 23% 23% 7% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)41.815412
GSM780708Untreated after 4 days (C2_1)38.02723
GSM780709Untreated after 4 days (C3_1)40.49358
GSM780719Untreated after 4 days (C1_2)42.558115
GSM780720Untreated after 4 days (C2_2)43.992722
GSM780721Untreated after 4 days (C3_2)45.287329
GSM780710Trastuzumab treated after 4 days (T1_1)42.794717
GSM780711Trastuzumab treated after 4 days (T2_1)42.802817
GSM780712Trastuzumab treated after 4 days (T3_1)48.571443
GSM780722Trastuzumab treated after 4 days (T1_2)42.69316
GSM780723Trastuzumab treated after 4 days (T2_2)40.56218
GSM780724Trastuzumab treated after 4 days (T3_2)42.49315
GSM780713Pertuzumab treated after 4 days (P1_1)44.33924
GSM780714Pertuzumab treated after 4 days (P2_1)39.73516
GSM780715Pertuzumab treated after 4 days (P3_1)43.35319
GSM780725Pertuzumab treated after 4 days (P1_2)43.889722
GSM780726Pertuzumab treated after 4 days (P2_2)39.31535
GSM780727Pertuzumab treated after 4 days (P3_2)40.58818
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)37.41742
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)43.835621
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)44.208423
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)44.227923
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)40.28967